CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB

Anticancer Research

Volumn 25, Issue 1 B, 2005, Pages 617-622

  Bouda, Jiri ^a   Boudova, L ^a   Hes, O ^a   Havir, M ^a   Tempfer, C ^b   Kohlberger, P ^c   Svoboda, T ^a   Rokyta, Z ^a   Speiser, P ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF FREIBURG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CD44v6; Cervical carcinoma; Prognostic factors

Indexed keywords

CD44V6 ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POPULATION RISK; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD44; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 16344381127     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Naot D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997.
2. Shimabukuro K, Toyama-Sorimachi N, Ozaki Y, Goi T, Furukawa K, Miyasaka M, Aso T and Toyamo-Sorimachi N: The expression patterns of standard and variant CD44 molecules in normal uterine cervix and cervical cancer. Gynecol Oncol 64(1): 26-34, 1997.
3. Dall P, Heider KH, Hekele A, von Minckwitz G, Kaufmann M, Ponta H and Herrlich P: Surface protein expression and messenger RNA-splicing analysis of GD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 54(13): 3337-41, 1994.
4. Dellas A, Schultheiss E, Almendral AC, Torhost J and Gudat F: Expression of CD44 and variant isoforms in cervical intraepithelial neoplasia. Gynecol Oncol 62(2): 218-25, 1996.
5. Kohlberger PD, Kieback DG, Bancher D, Stickeler E, Heinzl H, Gitsch G, Breitenecker G and Kainz C: Immunohistochemical detection of CD44 splice variant expression in premalignant lesions of the cervix and benign cervical epithelium. Gynecol Oncol 66(2): 227-32, 1997.
6. Ayhan A, Baykal C and Al A: Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma. Gynecol Oncol 83(3): 569-74, 2001.
7. Biesold C, Kohler U, Horn LC, Bilek K, Kade R and Emmert C: CD 44 exon v6 as a predictor of lymphatic metastases in cervical carcinoma-an immunocytochemical study of 94 cases. Arch Gynecol Obstet 256(3): 147-53, 1995.
8. Gadducci A, Ferdeghini M, Cosio S, Annicchiarico C, Fanucchi A, Prontera C, Bianchi R and Genazzani AR: The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer. Anticancer Res 18(1B): 537-9, 1998.
9. Saegusa M, Hashimura M, Machida D and Okayasu I: Down-regulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumours. J Pathol 187(2): 173-83, 1999.
10. Speiser P, Wanner C, Tempfer C, Mittelbock M, Hanzal E, Bancher-Todesca D, Gitsch G, Reinthaler A and Kainz C: CD44 is an independent prognostic factor in early-stage cervical cancer. Int J Cancer 74(2): 185-8, 1997.
11. Speiser P, Kridelka F, Tempfer C, Edwards L, Leodolter S, Kainz C and Hacker NF: CD44v6 expression is an independent prognostic factor in node-negative FIGO stage IB cervical carcinoma. Int J Gynecol Cancer 9(2): 160-165, 1999.
12. Tokumo K, Kodama J, Seki N, Miyagi Y, Yoshinouchi M and Kudo T: CD44 exon v6 correlates with cellular differentiation but not with progression and metastasis of cervical cancer. Eur J Cancer 34(13): 2107-11, 1998.
13. Dall P, Hekele A, Ikenberg H, Goppinger A, Bauknecht T, Pfleiderer A, Moll J, Hofmann M, Ponta H and Herrlich P: Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis. Int J Cancer 69(2): 79-85, 1996.
14. Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G, Reinthaller A and Breitenecker G: Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur J Cancer 31A(10): 1706-9, 1995.
15. Kainz C, Kohlberger P, Sliutz G, Tempfer C, Heinzl H, Reinthaller A, Breitenecker G and Koelbl H: Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol 57(3): 383-7, 1995.
16. Kainz C, Tempfer C, Kohlberger P, Janisch S, Koelbl H, Gitsch G and Breitenecker G: Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer. Int J Cancer 69(3): 170-3, 1996.
17. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT and Major F: Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38(3): 352-7, 1990.
18. Burghardt E, Pickel H, Haas J and Lahousen M: Prognostic factors and operative treatment of stages IB to IIB cervical cancer. Am J Obstet Gynecol 156(4): 988-96, 1987.
19. Stendahl U, Willen H and Willen R: Invasive squamous cell carcinoma of the uterine cervix. I. Definition of parameters in a histopathologic malignancy grading system. Acta Radiol Oncol 19(6): 467-80, 1980.
20. Ekici S, Ayhan A, Kendi S and Ozen H: Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. J Urol 167(5): 2037-41, 2002.
21. Hoshimoto K, Yamauchi N, Takazawa Y, Onda T, Taketani Y and Fukayama M: CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker. Pathol Res Pract 199(2): 71-7, 2003.
22. Jansen RH, Joosten-Achjanic SR, Arends JW, Volovics A, Hupperets PS, Schouten HC and Hillen HF: CD44v6 is not a prognostic factor in primary breast cancer. Ann Oncol 9(1): 109-11, 1998.
23. Kurozumi K, Nishida T, Nakao K, Nakahara M and Tsujimoto M: Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer. World J Surg 22(8): 853-7; discussion 857-8, 1998.
24. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M and Eskelinen M: Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 186(2): 157-64, 1998.
25. Morrin M and Delaney PV: CD44v6 is not relevant in colorectal tumour progression. Int J Colorectal Dis 17(1): 30-6, 2002.
26. Tempfer C, Sliutz G, Haeusler G, Speiser P, Reinthaller A, Breitenecker G, Vavra N and Kainz C: CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer. Br J Cancer 78(8): 1091-4, 1998.
27. Tokumo K, Kodama J, Seki N, Miyagi Y, Yoshinouchi M and Kudo T: CD44 exon v6 is not implicated in the progression and metastasis of endometrial cancer. Cancer Lett 125(1-2): 221-5, 1998.
28. Look KY, Brunetto VL, Clarke-Pearson DL, Averette HE, Major FJ, Alvarez RD, Homesley HD and Zaino RJ: An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 63(3): 304-11, 1996.
29. Gorham H, Woodman A, Goodison S, Marsh J, Charnock M, Manek S, Sugino T and Tarin D: CD44 expression in cervical intraepithelial neoplasia (C1N) and carcinoma. Mol Diagn 4(1): 45-56, 1999.
30. Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ, Holzel F, Maass H and Gunthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55(22): 5424-33, 1995.